Towards Healthcare

DNA Diagnostics Companies, Corporate Milestones, Corporate Growth and Development Strategy, Mergers and Acquisitions (M&A), Intellectual Property (IP) Portfolio Management, Market Trends Analysis, Leadership Alignment with Trends

Date: November 2024

DNA Diagnostics Companies and Competitive Landscape

The DNA diagnostics market size was estimated at US$ 10.69 billion in 2023 and is projected to grow to US$ 17.44 billion by 2034, rising at a compound annual growth rate (CAGR) of 4.55% from 2024 to 2034.

DNA Diagnostics Market Companies

Top Companies in the DNA Diagnostics Market

  • Agilent Technologies, Inc.
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories
  • F. Hoffmann-La-Roche
  • Fisher Scientific
  • GE Healthcare
  • Illumina, Inc.
  • Myriad Genetics
  • Oxford Nanopore Technologies
  • Siemens Healthineers
  • Qiagen

Latest Announcements by Industry Leaders

Dr. Kevin Haas, Chief Technology Officer of Myriad Genetics, commented that genetic testing represents more than just scientific advancement; it’s a fundamental shift in the health and wellness approach. By fostering collaboration and seamless data integration, the industry is laying the groundwork for the future involving personalized medicine.

Recent Developments in the DNA Diagnostics Market

  • In June 2024, researchers from the Case Western Reserve University School of Medicine developed a novel method, AMPLON (Amplifying DNA with Multiarm Priming and Looping Optimization of Nucleic Acid), to target DNA amplification, testing, and analysis.
  • In November 2024, ProPhase Labs, Inc. announced the launch of DNA Complete, Inc., a wholly-owned subsidiary offering direct-to-consumer DNA tests that sequence virtually 100% of a customer’s genome.

If you have any questions, please feel free to contact us at sales@towardshealthcare.com